NFL Biosciences SA (EPA:ALNFL)
France · Delayed Price · Currency is EUR 0.5500
-0.0100 (-1.79%)
Oct 23, 2026, 9:13 AM CEST
NFL Biosciences Revenue
NFL Biosciences had revenue of 30.00 EUR in the half year ending December 31, 2025. This brings the company's total for the last twelve months to 3.15K, up 1,817.68% year-over-year. In the year 2025, NFL Biosciences had annual revenue of 188.00 with 308.70% growth. That makes NFL Biosciences the 47,733rd largest company in the world by revenue and 635th in France.
Revenue (ttm)
3.15K
Revenue Growth
+1,817.68%
P/S Ratio
37,747.11
Revenue / Employee
47.00
Employees
4
Market Cap
6.97M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 188.00 | 142.00 | 308.70% |
| Dec 31, 2024 | 46.00 | -199.97K | -99.98% |
| Dec 31, 2023 | 200.01K | 199.99K | 909,040.91% |
| Dec 31, 2022 | 22.00 | -17.00 | -43.59% |
| Dec 31, 2021 | 39.00 | 36.00 | 1,200.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| genOway Société anonyme | 24.58M |
| Advicenne | 10.74M |
| Poxel | 7.66M |
| Aelis Farma | 2.19M |
| Oncodesign Precision Medicine Société anonyme | 1.81M |
| Plant Advanced Technologies | 1.37M |
| Aton | 661.00K |
| TME Pharma | 27.00K |